Pulmonary toxicity during chemotherapy with etopiside and carboplatin Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003
Carboplatin and paclitaxel chemotherapy for lung cancer patients with interstitial lung disease Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Combination chemotherapy with gemcitabine using isolated lung perfusion for the treatment of lung metastases Source: Eur Respir J 2004; 24: Suppl. 48, 42s Year: 2004
Non-small cell lung cancer treatment: chemotherapy combination gemcitabine – cisplatin – paclitaxel Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004
Concurrent chemoradiotherapy with carboplatin and paclitaxel followed by consolidation chemotherapy with vinorelbine for locally advanced inoperable nonsmall-cell lung cancer: A multiinstitutional phase II study Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Cisplatin and docetaxel induction chemotherapy results Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005
Consolidation maintenance oral vinorelbine following concurrent chemoradiation of intravenous vinorelbine and cisplatin in patients with unresectable stage III non-small cell lung cancer Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015
Pegylated liposomal doxorubicin compared with traditional doxorubicin in combination chemo-radiotherapy for small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 465s Year: 2002
Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC Source: ERJ Open Res, 3 (1) 00128-2016; 10.1183/23120541.00128-2016 Year: 2017
The effectiveness of vinorelbine plus cisplatin versus gemcitabine plus cisplatin in local advanced non small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 752s Year: 2006
Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013
Effectivity of chemotherapy regimen included carboplatin, ifosfamide, etoposide with or without adding interferon alpha 2a in treatment of patients with small cell lung carcinoma Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005
Combination of oral and parenteral vinorelbine with cisplatin or carboplatin in adjuvant chemotherapy of nonsmall cell lung cancer - SWITCH study Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015
A phase II trial in patients with extensive disease small-cell lung cancer with irinotecan, carboplatin and etoposide regimen as a first line treatment Source: Eur Respir J 2006; 28: Suppl. 50, 781s Year: 2006
Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 301s Year: 2004
First line treatment with gemcitabine plus cisplatine in non-small cell lung cancer: a comparison with etoposide plus cisplatin Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005
Economic evaluation of gemcitabine plus cisplatin (GD) versus vinorelbine plus cisplatin plus Ifosfamide (NIP) in patients with locally advanced or metastatic non-small-cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003
Pegylated liposomal doxorubicin HCl (Caelyx) in combination with sandostatin LAR as salvage therapy in patients with small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005
Sequential monochemotherapy: vepesid (VP16) and carboplatin (CBDCA) in the treatment of elderly patients with small cell lung cancer (SCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 395s Year: 2001
Effects of treatment with etoposide and cisplatinum in nonsmall cell lung cancer patients-a single institution experience Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001